Alcohol dependence is a medical condition in which a person has a strong, often uncontrollable need to drink alcohol, experiences withdrawal symptoms when not drinking, and continues drinking despite harm. For investors, it matters because rates of alcohol dependence affect demand for treatments, public health spending, insurance costs, workplace productivity, and regulatory or legal risks for companies in healthcare, insurance, food & beverage, and occupational sectors—think of it as a market factor that can change steady demand patterns.
opioid dependencemedical
Opioid dependence is a medical condition in which a person’s body adapts to regular opioid use so that stopping or reducing the drug causes withdrawal symptoms; think of it like a routine the body learns and then struggles to break. For investors, it matters because the prevalence, treatment options, regulatory scrutiny, and legal exposure around dependence shape demand for medications and devices, affect healthcare costs and reimbursement, and influence the financial risks and opportunities for companies in pharmaceuticals, medical services, and diagnostics.
schizophreniamedical
A chronic brain disorder that changes how a person thinks, perceives reality, feels and interacts with others, often causing hallucinations, false beliefs and trouble organizing thoughts or daily life. It matters to investors because the condition creates demand for long‑term treatments, diagnostics and support services; developing effective therapies can be costly, risky and highly regulated, but successful drugs or devices can open large, steady markets—think of it like fixing a deep, complex software bug that many users rely on.
bipolar I disordermedical
A mental health condition marked by at least one episode of mania—periods of unusually high energy, impulsive behavior and racing thoughts—often alternating with episodes of depression. Investors watch it because treatments, diagnostic tools and care models for this condition shape pharmaceutical and medical-device markets, clinical trial activity, insurance costs and workplace productivity; think of it as a visible driver of healthcare spending and regulatory risk in mental-health-related investments.
narcolepsymedical
A chronic neurological condition that causes sudden, uncontrollable episodes of deep sleep and extreme daytime drowsiness, like a phone that unexpectedly shuts off during the day. It matters to investors because it defines the market need for treatments, influences clinical trial results and regulatory decisions, and can drive revenue or risk for companies developing medications, devices, or diagnostics tied to sleep disorders.
idiopathic hypersomniamedical
A chronic sleep disorder that causes extreme daytime sleepiness and prolonged, unrefreshing sleep despite adequate night sleep, with no identifiable medical or neurological cause. Think of it like a phone battery that won’t hold charge: sufferers remain tired and less productive even after long rest. For investors, idiopathic hypersomnia matters because it creates demand for treatments, diagnostics and supportive services, influencing market opportunities and regulatory pathways in sleep medicine.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
DUBLIN--(BUSINESS WIRE)--
Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, Jan. 13, 2026 at 10:30 a.m. PST (1:30 p.m. EST/6:30 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.
